Evidence map›Paper›PMID 33031826›Full record

ReviewLife sciences2020

CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.

Abu Hazafa, Muhammad Mumtaz, Muhammad Fras Farooq, Shahid Bilal, Sundas Nasir Chaudhry, Musfira Firdous, Huma Naeem, Muhammad Obaid Ullah, Muhammad Yameen, Muhammad Shahid Mukhtiar and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Unzipping the defense: a comprehensive review on bZIP transcription factors inFrontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Abu HazafaDepartment of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan. Electronic address: Abu.9093270@talmeez.pk.
Muhammad MumtazDepartment of Chemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan.
Muhammad Fras FarooqDepartment of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan.
Shahid BilalDepartment of Agronomy, Faculty of Agriculture, University of Agriculture, Faisalabad 38000, Pakistan.
Sundas Nasir ChaudhryDepartment of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan.
Musfira FirdousDepartment of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan.
Huma NaeemDepartment of Computer Science, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan.
Muhammad Obaid UllahDepartment of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan.
Muhammad YameenDepartment of Biochemistry, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan. Electronic address: myameen@gcuf.edu.pk.
Muhammad Shahid MukhtiarDepartment of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38000, Pakistan.
Fatima ZafarInstitute of Biochemistry and Biotechnology, University of the Punjab, Lahore 54590, Pakistan.
University of Agriculture Faisalabad · PKGovernment College University, Faisalabad · PKUniversity of the Punjab · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the most leading causes of death and a major public health problem, universally. According to accumulated data, annually, approximately 8.5 million people died because of the lethality of cancer. Recently, a novel RNA domain-containing endonuclease-based genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) have been proved as a powerful technique in the treatment of cancer cells due to its multifunctional properties including high specificity, accuracy, time reducing and cost-effective strategies with minimum off-target effects. The present review investigates the overview of recent studies on the newly developed genome-editing strategy, CRISPR/Cas9, as an excellent pre-clinical therapeutic option in the reduction and identification of new tumor target genes in the solid tumors. Based on accumulated data, we revealed that CRISPR/Cas9 significantly inhibited the robust tumor cell growth (breast, lung, liver, colorectal, and prostate) by targeting the oncogenes, tumor-suppressive genes, genes associated to therapies by inhibitors, genes associated to chemotherapies drug resistance, and suggested that CRISPR/Cas9 could be a potential therapeutic target in inhibiting the tumor cell growth by suppressing the cell-proliferation, metastasis, invasion and inducing the apoptosis during the treatment of malignancies in the near future. The present review also discussed the current challenges and barriers, and proposed future recommendations for a better understanding.

Indexed as

CRISPR-Cas SystemsGene EditingGenetic TherapyGenome, HumanHumansNeoplasmsCRISPR/Cas9Genome editingOff-targetRNA editingSolid tumorViral delivery

Identifiers

PMID33031826
PMCPMC7533657
OpenAlexW3092100989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.